Mazdutide vs Retatrutide
Mazdutide (LY3305677, also IBI362) and Retatrutide (LY3437943) both activate the glucagon receptor, which sets them apart from semaglutide and tirzepatide. Mazdutide is a dual GLP-1 and glucagon receptor agonist; Retatrutide adds the GIP receptor to make a triple agonist. This page compares them as research compounds.
| Mazdutide | Retatrutide | |
|---|---|---|
| Development code | LY3305677 (IBI362) | LY3437943 |
| Receptor targets | GLP-1 and glucagon (dual) | GLP-1, GIP and glucagon (triple) |
| Molecule | Oxyntomodulin analogue | Single-peptide triple agonist |
| Administration in trials | Once weekly subcutaneous | Once weekly subcutaneous |
| Phase 3 obesity result | GLORY-1: 11.0% (4mg) and 14.0% (6mg) at 48 weeks, placebo +0.3% | TRIUMPH-1: 17.6% to 25.0% at 80 weeks, placebo 3.9% |
| Status | Approved in China in 2025 | Phase 3; a US filing is planned for early 2027 |
| Peptx availability | UK single vials (10mg) and Factory Direct kits | UK single vials and Factory Direct kits |
- Development code
- LY3305677 (IBI362)LY3437943
- Receptor targets
- GLP-1 and glucagon (dual)GLP-1, GIP and glucagon (triple)
- Molecule
- Oxyntomodulin analogueSingle-peptide triple agonist
- Administration in trials
- Once weekly subcutaneousOnce weekly subcutaneous
- Phase 3 obesity result
- GLORY-1: 11.0% (4mg) and 14.0% (6mg) at 48 weeks, placebo +0.3%TRIUMPH-1: 17.6% to 25.0% at 80 weeks, placebo 3.9%
- Status
- Approved in China in 2025Phase 3; a US filing is planned for early 2027
- Peptx availability
- UK single vials (10mg) and Factory Direct kitsUK single vials and Factory Direct kits
Glucagon is the shared idea
Both molecules pair GLP-1 receptor activity with glucagon receptor activity. In animal studies glucagon signalling raises energy expenditure and drives fat breakdown in the liver, while the GLP-1 arm offsets glucagon's tendency to raise blood glucose. Retatrutide adds a third target, the GIP receptor, which it shares with tirzepatide.
Mazdutide is described as an oxyntomodulin analogue: oxyntomodulin is the gut hormone that naturally activates both the GLP-1 and glucagon receptors. Retatrutide is a single engineered peptide built to activate all three receptors.
What the Phase 3 trials show
Mazdutide's GLORY-1 trial, published in the New England Journal of Medicine in 2025, enrolled 610 Chinese adults with overweight or obesity. At 48 weeks body weight fell 11.0% on 4mg and 14.0% on 6mg, against a 0.3% gain on placebo. A higher 9mg dose in GLORY-2, published in JAMA in 2026, reached 16.7% at 60 weeks against 1.5% on placebo.
Retatrutide's TRIUMPH-1 trial, published in the New England Journal of Medicine in September 2026, enrolled 2,339 adults in several countries, including the UK. At 80 weeks body weight fell 17.6%, 23.7% and 25.0% on 4mg, 9mg and 12mg, against 3.9% on placebo.
The programmes differ in population, BMI thresholds and length, so the figures are not a head-to-head comparison, and no trial has tested the two against each other.
Liver fat
Both compounds have reported large falls in liver fat. In GLORY-1, participants who started with at least 10% liver fat saw it fall by 65.9% on 4mg and 80.2% on 6mg at 48 weeks, against 5.3% on placebo. In a 24-week retatrutide sub-study published in Nature Medicine in 2024, liver fat fell 82.4% on 12mg.
Bottom line for research labs
Mazdutide and Retatrutide are the two glucagon-containing compounds researchers compare most. Retatrutide has the larger Phase 3 dataset and the bigger reported effect. Mazdutide is the dual-agonist reference, with a growing record in diabetes and liver-fat research. Labs studying what the GIP arm adds often work with both.